Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 41NIH 4INDUSTRY 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Carcinoma, Non-Small-Cell Lung 687Breast Neoplasms 585Neoplasms 468Colorectal Neoplasms 300Prostatic Neoplasms 263Neoplasm Metastasis 257Melanoma 242Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 196Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 142Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Squamous Cell Carcinoma of Head and Neck 113Head and Neck Neoplasms 113Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Small Cell Lung Carcinoma 96Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 77Triple Negative Breast Neoplasms 73

Interventions

Lapatinib 2pembrolizumab 1pazopanib 1bemcentinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Inflammatory Breast Neoplasms × Clear all
NCT03184558 2021-11-09

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

BerGenBio ASA

Phase 2 Terminated
29 enrolled 10 charts
Breast

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00105950 2015-09-28

Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

GlaxoSmithKline

Phase 2 Completed
126 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00558103 2013-02-04

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

GlaxoSmithKline

Phase 2 Completed
163 enrolled 14 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡